news
Two drug candidates show promise against COVID-19 in organoid system
Following their success in organoid systems, two drug candidates are now to be administered to ferrets and tested against COVID-19.
List view / Grid view
Therapeutics
news
Treatments for macrophage activation syndrome could reduce COVID-19 mortality
Researchers suggest possible therapies for macrophage activation syndrome (MAS), a feature of cytokine storm and a major cause of death in severe COVID-19 patients.
article
Expert view: Increasing the efficiency of biologics development: the secret is precise and reliable stability characterisation of candidate molecules
Biologics are becoming increasingly important for the treatment of a wide variety of diseases, with more biologics receiving regulatory approval from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and entering the clinic every year.
article
Targets In-Depth Focus 2020
This in-depth focus includes articles on the importance of a novel target to treat M. tuberculosis infections and how recently identified interactions between the SARS-CoV-2 Spike protein and host epithelial cells could be used in the development of COVID-19 therapeutics.
article
Drug Target Review – Issue 3 2020
This issue includes articles that explore how a next-generation genomics platform can be used for COVID-19 research, the elimination of neutralising AAV antibodies for gene therapies and a new quick and cost-effective biomarker technology for cancer diagnostics. Also in this issue are features on antibody therapeutics for COVID-19 and targets…
news
Novel lysin-based antibacterial agent could help combat MRSA
Researchers have engineered F12, a lysin-based antibacterial drug, to have limited negative side-effects and so it can be administered repeatedly without loss of efficacy.
news
Engineered protein could be used to treat type 2 diabetes
An engineered form of the SMOC1 protein has shown success as a type 2 diabetes treatment in animal models, say researchers.
news
UK government to invest £8.4 million into COVID-19 immunology research
The UK government will invest £8.4 million in COVID-19 research projects to reveal more information that can be used to develop therapies and vaccines against the disease.
news
Novel CAR T-cell therapy could help cure HIV
The designers of the Dual Chimeric Antigen Receptor (CAR) T cell therapy report it slows HIV replication and leads to a smaller viral reservoir in HIV-infected mice.
news
Novel GI tract coating could deliver drugs, aid digestion or control obesity
The developers of a temporary coating which adheres to the small intestine demonstrated it could be modified to deliver drugs, aid digestion and stop absorption of glucose.
news
Novel targeted treatment shows efficacy in treating high-risk solid tumours
The prodrug developed by researchers caused long-term remission in all murine models of high-risk or drug-resistant cancers with fewer side-effects than a comparable drug.
news
Researchers suggest IgA antibodies are better at neutralising SARS-CoV-2
Scientists have developed a novel secretory immunoglobulin A (sIgA) serotype antibody that binds more effectively to the spike protein of SARS-CoV-2 than some IgG antibodies.
news
Could STING activation be the target of future cancer immunotherapies?
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
news
Inhibiting sortilin could make pancreatic cancer therapies more effective
A study has shown that inhibiting sortilin, a neuroprotein known to have increased expression in cancers, reduces pancreatic cancer invasiveness in vitro.
news
AI holds promise to accelerate drug repurposing for COVID-19
According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
